Methysergide clinical pharmacology: Difference between revisions
Gerald Chi (talk | contribs) Created page with "__NOTOC__ {{Methysergide}} {{CMG}} == <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SANSERT (METHYSERGIDE MALEATE) TABLET, COATED [NOVARTIS P..." |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== | ==Actions== | ||
Sansert® (methysergide maleate) has been shown, in vitro and in vivo, to inhibit or block the effects of serotonin, a substance which may be involved in the mechanism of vascular headaches. Serotonin has been variously described as a central neurohumoral agent or chemical mediator, as a “headache substance” acting directly or indirectly to lower pain threshold (others in this category include tyramine; polypeptides, such as bradykinin; histamine; and acetylcholine), as an intrinsic “motor hormone” of the gastrointestinal tract, and as a “hormone” involved in connective tissue reparative processes. Suggestions have been made by investigators as to the mechanism whereby methysergide produces its clinical effects, but this has not been finally established.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SANSERT (METHYSERGIDE MALEATE) TABLET, COATED [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fae28ee-700e-4d4f-a040-02ef01a2aeb4 | publisher = | date = | accessdate = }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SANSERT (METHYSERGIDE MALEATE) TABLET, COATED [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fae28ee-700e-4d4f-a040-02ef01a2aeb4 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 19:27, 7 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Actions
Sansert® (methysergide maleate) has been shown, in vitro and in vivo, to inhibit or block the effects of serotonin, a substance which may be involved in the mechanism of vascular headaches. Serotonin has been variously described as a central neurohumoral agent or chemical mediator, as a “headache substance” acting directly or indirectly to lower pain threshold (others in this category include tyramine; polypeptides, such as bradykinin; histamine; and acetylcholine), as an intrinsic “motor hormone” of the gastrointestinal tract, and as a “hormone” involved in connective tissue reparative processes. Suggestions have been made by investigators as to the mechanism whereby methysergide produces its clinical effects, but this has not been finally established.[1]
References
Adapted from the FDA Package Insert.